Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 4:01 PM
Ignite Modification Date:
2025-12-26 @ 4:01 PM
NCT ID:
NCT04338906
Eligibility Criteria:
Inclusion Criteria:
* Participants ≥18 years of age with SARS-CoV-2 infection confirmed by PCR before randomization
* Willing and able to provide written informed consent
* Hospitalized and requiring medical care for COVID-19, (status 3 or 4 of 7-point ordinal clinical status scale)
* SpO2 ≥93% on room air
* Evidence of pulmonary infiltrate on chest X ray/and or CT scan
Exclusion Criteria:
* Age \<18 years old
* Pregnant or breast feeding
* Inability to take oral medication
* Inability to provide informed written consent
* Known hypersensitivity towards 4-aminoquinolines, e.g. hydroxychloroquine and/or camostat
* Use of hydroxychloroquine, chloroquine and or camostat within 6 months prior to baseline
* Patients with known retinopathy or macular degeneration Patients with known glucose-6-phosphate dehydrogenase (G6PD) deficiency
* Prolonged QTc-interval in baseline ECG (\>500 ms)
* Concomitant medication associated with QTc-interval prolongation, which cannot be withdrawn prior to study drug administration
* Major comorbidities, possibly leading to increased unwanted side effects of study drugs:
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04338906
Study Brief:
Protocol Section:
NCT04338906